Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects and Safety of ODM-111 and Paracetamol for Chronic Knee Pain in Osteoarthritis Patients

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects and safety of a new medication called ODM-111 for people experiencing long-lasting pain due to osteoarthritis of the knee. Osteoarthritis is a common joint condition that causes pain and stiffness, particularly in the knees. The study aims to evaluate how well ODM-111 works in reducing this chronic pain.

Participants in the study will receive either the new medication ODM-111, a commonly used pain reliever called Paracetamol (known as Para-Tabs 500 mg), or a placebo. The study will last for a period of six weeks, during which participants will take the medication orally in the form of tablets. The goal is to see if ODM-111 can effectively reduce knee pain compared to the other treatments.

Throughout the study, participants will be monitored to assess any changes in their pain levels and to ensure their safety. The primary focus is on the change in pain from the beginning of the study to the end of the six-week period, using a specific pain measurement scale. This research is important for finding new ways to help people manage chronic knee pain caused by osteoarthritis.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will attend an initial visit. During this visit, your eligibility for the trial will be confirmed based on specific criteria, such as age, body mass index (BMI), and the presence of chronic pain due to osteoarthritis in the knee.

    You will be asked to provide informed consent, which means you agree to participate in the study after understanding all the details and potential risks.

  2. Step 2

    Baseline assessments

    Baseline assessments will be conducted to evaluate your current condition. This includes measuring your pain levels using a scale called the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and a numerical rating scale (NRS).

    These assessments help establish a starting point for your pain levels before beginning the treatment.

  3. Step 3

    Treatment phase

    During the treatment phase, you will receive either the study medication ODM-111 or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drug.

    The medication will be administered orally in the form of tablets. The specific dosage and frequency will be provided by the study team.

    This phase will last for a specified duration, during which you will continue to take the medication as instructed.

  4. Step 4

    Follow-up visits

    You will attend regular follow-up visits to monitor your progress and any changes in your condition. These visits are important to ensure your safety and to assess the effectiveness of the treatment.

    During these visits, you will undergo similar assessments as the baseline to track changes in your pain levels and overall health.

  5. Step 5

    End of study visit

    At the end of the study, you will have a final visit to conclude your participation. This visit will include a comprehensive assessment of your condition and any effects of the treatment.

    You will be provided with information about the next steps and any follow-up care if necessary.

Who can join the trial?

8 criteria

  • Must provide a signed informed consent to participate in the trial.
  • Must be a male or female who is 40 years of age or older at the time of the screening visit.
  • Must have a Body Mass Index (BMI) between 18 and 40 kg/m2 at the screening visit. BMI is a measure of body fat based on height and weight.
  • Must have a diagnosis of osteoarthritis (OA) in the knee according to specific medical criteria and a certain grade of severity in the knee joint at the screening visit.
  • The knee osteoarthritis must be the main source of pain, and pain in the most affected knee must have been present for more than 6 months at the screening visit.
  • Must have a certain level of pain in the affected knee as measured by specific pain scales at both the screening and baseline visits.
  • Must be classified as ACR Functional class I-III, which refers to the level of physical function.
  • If female participants have male partners who can father children, or if male participants have female partners who can become pregnant, they must use a highly effective form of birth control if sexually active and not permanently sterilized. This applies to females from 4 weeks before the first study treatment and to males from Day 1 until 3 months after the end of the study. Women who have not had a menstrual cycle for 1 year are considered not able to have children and can be included. Male participants cannot donate sperm until 3 months after the end of the study.

Who cannot join the trial?

8 criteria

  • Patients who have any other significant health problems that could interfere with the study.
  • Patients who are currently participating in another clinical trial.
  • Patients who have had a knee surgery in the last 6 months.
  • Patients who are allergic to the study medication or its ingredients.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a history of drug or alcohol abuse.
  • Patients who are unable to follow the study procedures or instructions.
  • Patients who have a condition that affects their ability to give informed consent.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

ODM-111 is a medication being studied for its ability to help manage chronic pain in people with knee osteoarthritis. Osteoarthritis is a condition that causes the joints to become painful and stiff. This medication is being tested to see if it can reduce the pain and improve the quality of life for those suffering from this condition. The trial aims to find out how well ODM-111 works and how well people can tolerate it, meaning how it affects them and if there are any side effects.

What is already known about the treatment

ODM-111 – ODM-111 is administered orally in the form of tablets and is currently being studied for its effectiveness in treating chronic pain caused by osteoarthritis of the knee. It is in the clinical trial phase, where researchers are evaluating its safety and how well it works. The main purpose of ODM-111 is to help reduce pain and improve joint function in people with knee osteoarthritis. At the molecular level, it works by targeting specific pathways in the body that are involved in pain and inflammation, helping to alleviate discomfort. It is classified as an analgesic, which is a type of medication used to relieve pain.

Investigated diseases

Osteoarthritis of the Knee – Osteoarthritis of the knee is a degenerative joint disease characterized by the breakdown of cartilage in the knee joint. As the cartilage wears away, bones begin to rub against each other, causing pain, swelling, and reduced motion in the joint. Over time, the joint may become stiff and lose its normal shape. Small bone growths, called osteophytes or bone spurs, may form around the joint. The condition typically progresses slowly, with symptoms worsening over time. It is most common in older adults and can be influenced by factors such as age, weight, and previous joint injuries.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-513553-79-00Protocol code3133003Estimated enrolment294 patientsSponsorOrion Corporation

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).